Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece. Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Clin Cancer Res. 2016 Apr 15;22(8):2032-40. doi: 10.1158/1078-0432.CCR-15-1170. Epub 2015 Dec 8.
Prompted by the extensive biases in the immunoglobulin (IG) gene repertoire of splenic marginal-zone lymphoma (SMZL), supporting antigen selection in SMZL ontogeny, we sought to investigate whether antigen involvement is also relevant post-transformation.
We conducted a large-scale subcloning study of the IG rearrangements of 40 SMZL cases aimed at assessing intraclonal diversification (ID) due to ongoing somatic hypermutation (SHM).
ID was identified in 17 of 21 (81%) rearrangements using the immunoglobulin heavy variable (IGHV)1-204 gene versus 8 of 19 (40%) rearrangements utilizing other IGHV genes (P= 0.001). ID was also evident in most analyzed IG light chain gene rearrangements, albeit was more limited compared with IG heavy chains. Identical sequence changes were shared by subclones from different patients utilizing the IGHV1-204 gene, confirming restricted ongoing SHM profiles. Non-IGHV1-2*04 cases displayed both a lower number of ongoing SHMs and a lack of shared mutations (per group of cases utilizing the same IGHV gene).
These findings support ongoing antigen involvement in a sizable portion of SMZL and further argue that IGHV1-2*04 SMZL may represent a distinct molecular subtype of the disease.
由于脾脏边缘区淋巴瘤 (SMZL) 的免疫球蛋白 (IG) 基因库中存在广泛的偏倚,支持 SMZL 发生过程中的抗原选择,我们试图研究抗原是否也与转化后相关。
我们对 40 例 SMZL 病例的 IG 重排进行了大规模的亚克隆研究,旨在评估由于持续的体细胞超突变 (SHM) 而导致的克隆内多样化 (ID)。
与使用其他 IGHV 基因的 19 个重排中的 8 个 (40%) 相比,使用 IGHV1-204 基因的 21 个重排中的 17 个 (81%) 鉴定出 ID(P=0.001)。在大多数分析的 IG 轻链基因重排中也可以看到 ID,尽管与 IG 重链相比,ID 更为有限。使用 IGHV1-204 基因的不同患者的亚克隆共享相同的序列变化,证实了受限的持续 SHM 谱。非 IGHV1-2*04 病例表现出较少的持续 SHM 和缺乏共享突变(每个使用相同 IGHV 基因的病例组)。
这些发现支持在相当一部分 SMZL 中持续存在抗原参与,并进一步表明 IGHV1-2*04 SMZL 可能代表该疾病的一个独特的分子亚型。